Clinical Trials Sponsored by Miltenyi Biotec, Inc.

Total 463 results

Miltenyi Biotec, Inc.

Terminated

Stem Cell Implantation in Patients Undergoing CABG

Coronary Artery Disease | Ischemic Cardiomyopathy

United States
Hospital Israelita Albert Einstein
Miltenyi Biotec, Inc.

Not yet recruiting

A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies (CARTHIAE-1)

Acute Lymphoblastic Leukemia, in Relapse | B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent | Chronic Lymphocytic Leukemia Recurrent | Chronic Lymphocytic Leukemia Refractory | Acute Lymphoblastic Leukemia Refractory

Brazil
University Health Network, Toronto
Miltenyi Biotec, Inc.

Completed

IMPACT-CABG Trial: IMPlantation of Autologous CD133+ sTem Cells in Patients Undergoing Coronary Artery Bypass Grafting (IMPACT-CABG)

Heart Failure | Coronary Artery Bypass Surgery | Heart Attack

Canada
Miltenyi Biotec B.V. & Co. KG

Completed

Proof of Concept Study of IMMUNOadsorption Therapy in Patients With Idiopathic Pulmonary Arterial Hypertension

Idiopathic Pulmonary Arterial Hypertension

Germany
University of Alabama at Birmingham
Miltenyi Biotec, Inc.

Active, not recruiting

Standardization of CD3+ T Cell Dose for Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplantation From Matched Related Donors

Hematopoietic Stem Cell Transplantation

United States
Joanne Kurtzberg, MD
Duke University; Miltenyi Biotec, Inc.

Available

Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrelated Cord Blood Transplants

Hematologic Malignancies | Immune Deficiencies | Inborn Errors of Metabolism Disorders

United States
Julie-An M. Talano
Miltenyi Biotec, Inc.

Active, not recruiting

Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies With Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device

Hematologic Malignancies

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI); Miltenyi Biotec, Inc.

Completed

Hematopoietic Stem Cell Transplantation for Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using Total Body Irradiation, Cyclophosphamide and Fludarabine

Fanconi Anemia

United States
Miltenyi Biotec B.V. & Co. KG
German Federal Ministry of Education and Research

Terminated

Intramyocardial Transplantation of Bone Marrow Stem Cells in Addition to Coronary Artery Bypass Graft (CABG) Surgery (PERFECT)

Myocardial Ischemia | Coronary Artery Disease

Germany
M.D. Anderson Cancer Center
Miltenyi Biotec B.V. & Co. KG

Completed

Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation

Lymphoma | Leukemia

United States
Theratocular Biotek Co.

Recruiting

A Study to Investigate the Effect on Central Macular Thickness of Treatment With MG-O-1002 Eye Drops in Participants Aged Over 45 With Neovascular Age-related Macular Degeneration (nAMD)

Age-Related Macular Degeneration

Thailand
Yae-Jean Kim
Miltenyi Biotec B.V. & Co. KG

Withdrawn

Adoptive Transfer of pp65-specific T Cells for the Treatment of Refractory Cytomegalovirus (CMV) Infection

Cytomegalovirus Infections

Korea, Republic of
Miltenyi Biotec B.V. & Co. KG
University of Chicago; Ohio State University; Masonic Cancer Center, University...

Terminated

CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy for AML Patients Not in CR

Acute Myelogenous Leukemia

United States
UMC Utrecht
Boehringer Ingelheim; ZonMw: The Netherlands Organisation for Health Research... and other collaborators

Recruiting

Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis (UPSIDE)

Systemic Sclerosis | Scleroderma, Diffuse | Mycophenolate Mofetil | Scleroderma | Autologous Stem Cell Transplantation | Cyclophosphamide | Systemic Scleroses, Diffuse | Treatment Strategy

Italy, Switzerland, Netherlands, Sweden, United Kingdom
BioTex, Inc.

Not yet recruiting

Pivotal Voyager Ark Device Vascular Access Study (ACT II)

Vascular Access Complication | Dialysis; Complications
BioTex, Inc.

Completed

Laser Interstitial Thermal Therapy Under "Real Time" MRI Guidance for "Minimal Invasive" Treatment of Liver Metastasis

Digestive System Neoplasms | Carcinoma, Hepatocellular | Liver Neoplasms

France
BioTex, Inc.

Completed

MR Guided Laser Interstitial Thermal Therapy for the "Minimal Invasive" Treatment of Brain Metastasis and Primary Brain Tumors

Brain Neoplasms | Brain Cancer | Brain Tumor | Recurrent Brain Tumor

France
Theratocular Biotek Co.
Novotech (Australia) Pty Limited

Active, not recruiting

A Study to Investigate the Effect of IOP-lowering With TO-O-1001 Eye Drops in Healthy Subjects and in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open Angle Glaucoma

Australia
Tibotec, Inc
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received Treatment

HIV

United States
Tibotec, Inc
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men.

HIV | Infectious

United States, Canada, Puerto Rico
Tibotec, Inc
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients (INROADS)

Human Immunodeficiency Virus (HIV)

United States, Puerto Rico
Tibotec, Inc
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

A Phase I, Open-label Trial to Explore the Pharmacokinetics, Safety and Tolerability of TMC278 (Rilpivirine) 25 mg Once Daily Following a 2-week Period Receiving Efavirenz, in Healthy Male and Female Volunteers

HIV
Tibotec, Inc
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.

HIV

United States
Tibotec, Inc
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

A Study to Evaluate the Pharmacokinetic Profile (How the Body Absorbs, Distributes, Metabolizes and Eliminates a Drug) of TMC125 Plus Tenofovir/Emtricitabine Once Daily With or Without Darunavir/r Once Daily in Antiretroviral (ARV) Naive HIV-1 Patients (Patients Have Never Received ARV Treatment).

HIV-1 Infection
US Oncology Research
Ortho Biotech, Inc.; Tibotec Pharmaceutical Limited

Completed

Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer

Metastatic Breast Cancer

United States
VivaVision Biotech, Inc

Recruiting

Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery

Inflammation

United States
Krystal Biotech, Inc.

Recruiting

A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency (Serpentine-1)

Alpha 1-Antitrypsin Deficiency

United States
Krystal Biotech, Inc.

Recruiting

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

Cancer | Carcinoma, Squamous Cell | Carcinoma, Basal Cell | Osteosarcoma | Cutaneous Melanoma | Melanoma Stage IV | Melanoma Stage III

United States
Krystal Biotech, Inc.

Not yet recruiting

Topical KB105 for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)

Autosomal Recessive Ichthyosis

United States
Krystal Biotech, Inc.

Recruiting

Long-Term Follow-up Protocol

Dystrophic Epidermolysis Bullosa | Recessive Dystrophic Epidermolysis Bullosa | Dominant Dystrophic Epidermolysis Bullosa

United States
Johnpro Biotech, Inc.

Recruiting

Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBM

Glioblastoma

Taiwan
Janssen Biotech, Inc.

Active, not recruiting

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease (DEVELOP)

Inflammatory Bowel Diseases | Crohn's Disease | Ulcerative Colitis | Indeterminate Colitis

United States, Canada
Krystal Biotech, Inc.

Completed

A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa

Dystrophic Epidermolysis Bullosa | Recessive Dystrophic Epidermolysis Bullosa | Dominant Dystrophic Epidermolysis Bullosa | DEB - Dystrophic Epidermolysis Bullosa

United States
NKGen Biotech, Inc.

Active, not recruiting

Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy

Solid Tumor | Metastatic Cancer | Advanced Solid Tumor | Advanced Cancer | Solid Tumor, Adult | Refractory Cancer | Recurrent Cancer | Pathologically Confirmed Cancer Refractory to Conventional Therapy

United States
NKGen Biotech, Inc.

Terminated

Safety of SNK01 in Subjects With Alzheimer's Disease (ASK-AD) (ASK-AD)

Alzheimer Disease | Neuro-Degenerative Disease

Mexico
Maxigen Biotech Inc.

Completed

The Clinical Trial of Difference Between Formaderm Lidocaine and Formaderm Dermal Filler Injection

Lidocaine | Hyaluronic Acid | Dermal Fillers

Taiwan
Maxigen Biotech Inc.

Completed

ArtiAid® Plus for Knee Osteoarthritis: A Post-market Study

Hyaluronic Acid

Taiwan
Moleculin Biotech, Inc.

Completed

Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute

Poland
SciVision Biotech Inc.

Completed

China Post-Market Clinical Follow-up of FACILLE®

Nasolabial Fold | Hyaluronic Acid | Dermal Filler
Moleculin Biotech, Inc.

Completed

Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute

United States
SciVision Biotech Inc.

Completed

Evaluate the Safety and Effectiveness of Sodium Hyaluronate When Used for the Correction of Nasolabial Folds

Lidocaine | Nasolabial Fold | Hyaluronic Acid | Dermal Filler

China
Aduro Biotech, Inc.

Completed

Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma

Malignant Pleural Mesothelioma

United States
Aduro Biotech, Inc.

Terminated

Safety of ADU-1604 in Adults With Metastatic Melanoma

Metastatic Melanoma

Spain, France
Timmune Biotech Inc.

Unknown

Treatment of Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy

Non-Hodgkin Lymphoma

China
JHL Biotech, Inc.

Terminated

A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients

B Cell Lymphoma

China
Janssen Biotech, Inc.

Completed

Golimumab Safety and Surveillance Program Using the Ingenix NHI Database

Rheumatoid Arthritis | Arthritis, Psoriatic | Ankylosing Spondylitis
Mycenax Biotech Inc.

Completed

Phase I, Pharmacokinetic, Safety and Tolerability Study in Healthy Volunteers

Pharmacokinetics

Australia
Janssen Biotech, Inc.

Completed

The Crohn's Therapy, Resource, Evaluation, and Assessment Tool Registry (TREAT)

Crohn's Disease
Welichem Biotech Inc.

Completed

A Safety/Efficacy Study of a Non-steroid, Topical Cream Treatment of Psoriasis Over 12-weeks (134993)

Psoriasis
Welichem Biotech Inc.

Completed

Non-steroid, Atopic Dermatitis Phase IIb 12-week Trial; Topical WBI-1001 Cream

Dermatitis, Atopic

Canada

Clinical Trials Sponsored by Miltenyi Biotec, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Oman

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations